# EDGAR Filing Document

**Accession Number:** 0000109657
**File Stem:** 0001641172-25-017364
**Filing Date:** 2025-7
**Character Count:** 2723
**Document Hash:** 577e47a5abfb6cbaf59f60c9f5c367ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-017364.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001641172-25-017364

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250701

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GT Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0000109657
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 941620407
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 505 MONTGOMERY STREET
- **STREET 2:** 10TH FLOOR
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** (800) 304-9888

**MAIL ADDRESS:**
- **STREET 1:** 505 MONTGOMERY STREET
- **STREET 2:** 10TH FLOOR
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OXIS INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 19940916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DDI PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DIAGNOSTIC DATA INC /DE/
- **DATE OF NAME CHANGE:** 19850312

**GT Biopharma, Inc.**

505 Montgomery Street, 10th Floor

San Francisco, California 94111

July 1, 2025

**VIA EDGAR**

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attn: Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **GT Biopharma, Inc.** |
|  | **Acceleration Request for Registration Statement on Form S-1** |
|  | **File No. 333-287963** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Act</u>"), GT Biopharma, Inc. (the "<u>Company</u>") hereby requests that the effective date of the above-referenced registration statement (the "<u>Registration Statement</u>") be accelerated to July 2, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

We request that we be notified of such effectiveness by a telephone call to Alan A. Lanis, Jr. of Baker & Hostetler LLP, counsel to the Company, at (310) 442-8850 and that such effectiveness also be confirmed in writing.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| GT Biopharma, Inc. | GT Biopharma, Inc. |
| By: | */s/ Alan Urban* |
|  | Alan Urban |
|  | Chief Financial Officer |

---